Navigation Links
Novus International to Present Scientific Findings on Prebiotics during Aquaculture Europe 2013

ST. LOUIS, Aug. 6, 2013 /PRNewswire/ -- Aquaculture Europe 2013 will take place in Trondheim, Norway on August 9th and Novus will be present to support this important international industry conference. The theme of this year's event, Making Sense of Science, implies setting priorities for knowledge generation.


"Novus is firmly committed to supporting the aquaculture industry, which continues to experience tremendous growth," notes Dr. Francisco Gomes, Executive Manager, Novus Aqua. "Novus embraces every opportunity it has to share the scientific research and information that is the foundation for the development of products and solutions that maximize efficiency and profitability at every stage in the aquaculture production chain."

Knowledge sharing is a key aspect of the organizational culture at Novus. "We're continually focusing on the needs of the animal and the understanding of our customer's value chain," noted Dr. Gomes. "We have invested extensive resources in the European marine fish industry. Through strategic partnerships with customers and research partners we have been able to achieve significant milestones in issues such as sea lice myxosporidia and enteritis."

Craig Browdy, Novus Executive Manager, Aquaculture Research, will be presenting a scientific abstract on Saturday, August 10th beginning at 10:50 a.m. Entitled, Mode of action and practical applications of the prebiotic PREVIDA® to improve fish health, the abstract will discuss the results of a series of in vitro, in vivo and ex vivo field and lab tests with PREVIDA®. In this research PREVIDA binded with bacterial binding receptors, which left them inaccessible to pathogens, encouraged selective fermentation allowing beneficial bacteria to completely exclude pathogens, and caused significant improvements in gut ultrastructure. These benefits resulted in a reduction of enteritis and improvement in performance in sensitive marine species.

PREVIDA® is a single-source material which has a consistent composition and is of 100 percent natural origin with no added chemicals. Introduced by Novus in 2011, this breakthrough prebiotic won the 2012 North American New Product Innovation Award for Prebiotics. PREVIDA is part of Novus Aqua Health Through Nutrition Solutions.  Our complete portfolio of gut environment modifiers together with our expertise have positioned our technologies as successful tools across the world and the industry.

To learn more about the comprehensive programs and products Novus has available to support the production efficiency and profitability of the aquaculture industry, visit the company's corporate web site at

About Novus International, Inc.

Novus International, Inc. is headquartered in metropolitan St. Louis, Missouri, U.S.A. and serves customers in nearly 100 countries around the world. A global leader in developing animal health and nutrition solutions, Novus's products include ALIMET® and MHA® feed supplements, ACTIVATE® nutritional feed acid, ACIDOMIX® preservative premixture, ADVENT® coccidiosis control, CIBENZA® feed additive, MINTREX® chelated trace mineral, SANTOQUIN® feed preservative, MERA™MET aquaculture feed additive, AGRADO® feed antioxidant and many other specialty ingredients. Stratum® Nutrition, a division of Novus Nutrition Brands, LLC, focuses on human nutrition through specialty and functional ingredients for manufacturers of foods, beverages and dietary supplements ( Novus is privately owned by Mitsui & Co. (U.S.A.), Inc. and Nippon Soda Co., Ltd. For more information visit

®NOVUS, ALIMET, MHA, ACTIVATE, ACIDOMIX, CIBENZA, MAAC, MINTREX, SANTOQUIN and AGRADO are trademarks of Novus International, Inc. and are registered in the United States and other countries. ®ADVENT is a trademark of Viridus Animal Health, LLC, and is registered in the United States and other countries. ®STRATUM NUTRITION is a trademark of Novus Nutrition Brands, LLC, and is registered in the United States and other countries. ®PREVIDA is a registered trademark of TIN, Inc.  ™MERA and SOLUTIONS SERVICE SUSTAINABILITY are trademarks of Novus International, Inc. © 2013 Novus International, Inc. All rights reserved.

CONTACTS: Tracy Barfield

Barbara Hansen

SOURCE Novus International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Novus International And Verenium Announce Important Progress In The Development Of Novel Enzymes For Animal Health & Nutrition
2. Novus Biologicals Hires David Eansor to Lead New Corporate-Development Effort
3. First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration
4. Mimedx Scientific Study Is Electronically Published in The International Wound Journal
5. GeneCell International, Miami’s Preferred Cord Blood Laboratory, is Pleased to Announce That July is National Cord Blood Awareness Month
6. Join Cornerstone Plastic Surgery for an Exclusive Evening with Internationally Reknowned New York Trained Plastic Surgeon Frederick A. Coville, MD
7. GeneCell International’s Director of Operations, Jose Cirino, Organizes A Series of Educational Seminars with South Florida's Leading Obstetricians and Gynecologist
8. Cellular Dynamics International Announces Launch of Initial Public Offering
9. New Research from SRI International Points to Biomarker that Could Track Huntingtons Disease Progression
10. Rocky Mountain Biologicals Joins International Serum Industry Association
11. Yongye International, Inc. Announces Common Stock Will Resume Trading on the NASDAQ Stock Market on June 17, 2013
Post Your Comments:
(Date:11/25/2015)... Mass. , Nov. 25, 2015 Harvard ... biotechnology company developing bioengineered organ implants for life-threatening conditions, ... present at the LD Micro "Main Event" investor conference ... The presentation will be webcast live and posted for ... be available at the conference for one-on-one meetings on ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, ... will participate in a fireside chat discussion at the ... New York . The discussion is scheduled for ... .  A replay will be available ... Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications and ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... company uBiome, were featured on AngelList early in their initial angel funding process. ... AngelList syndicate for individuals looking to make early stage investments in the microbiome ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 Paris ...   --> Paris from 17 th ... DERMALOG, the biometrics innovation leader, has invented the first combined ... on the same scanning surface. Until now two different scanners ... one scanner can capture both on the same surface. ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/10/2015)... 10, 2015 About signature ... helps to identify and verify the identity of ... as the secure and accurate method of authentication ... particular individual because each individual,s signature is highly ... when dynamic signature of an individual is compared ...
Breaking Biology News(10 mins):